{"id":3530,"date":"2015-11-25T20:33:35","date_gmt":"2015-11-25T20:33:35","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=3530"},"modified":"2015-11-25T20:33:35","modified_gmt":"2015-11-25T20:33:35","slug":"therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/","title":{"rendered":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab"},"content":{"rendered":"<p>AMB 2015, <strong>49<\/strong>, <span id=\"ctl00_Content1_UCAnzeigeArtikel1_AnzeigeNr\">85<\/span><\/p>\n<h2>Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab<\/h2>\n<p><b>Fazit:<\/b> In der FUTURE-2-Studie besserte der Anti-Interleukin-17A-Antik\u00f6rper Secukinumab in den h\u00f6heren hier verwendeten Dosierungen deutlich die Symptome bei Patienten mit aktiver Psoriasisarthritis. Allerdings waren in dieser Studie auch Patienten eingeschlossen worden, die bereits ein Glukokortikosteroid bzw. Methotrexat einnahmen.\u00a0 <a href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Artikel.aspx?J=2015&amp;S=85\"><strong>Bitte abonnieren oder Kennlernartikel anfordern &#8211;&gt;<\/strong><\/a><\/p>\n<p>&nbsp;<\/p>\n<p><b>Schlagworte zum Artikel<\/b><\/p>\n<p><a class=\"link\" href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Schlagwort.aspx?S=Psoriasis,\" target=\"_self\">Psoriasis,<\/a> <a class=\"link\" href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Schlagwort.aspx?S=Schuppenflechte,\" target=\"_self\">Schuppenflechte,<\/a> <a class=\"link\" href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Schlagwort.aspx?S=Psoriasisarthritis,\" target=\"_self\">Psoriasisarthritis,<\/a> <a class=\"link\" href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Schlagwort.aspx?S=Secukinumab,\" target=\"_self\">Secukinumab,<\/a> <a class=\"link\" href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Schlagwort.aspx?S=FUTURE-2-Studie,\" target=\"_self\">FUTURE-2-Studie,<\/a> <a class=\"link\" href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Schlagwort.aspx?S=Psoriasis,\" target=\"_self\">Psoriasis,<\/a> <a class=\"link\" href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Schlagwort.aspx?S=Schuppenflechte,\" target=\"_self\">Schuppenflechte,<\/a> <a class=\"link\" href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Schlagwort.aspx?S=Psoriasisarthritis,\" target=\"_self\">Psoriasisarthritis,<\/a> <a class=\"link\" href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Schlagwort.aspx?S=Secukinumab,\" target=\"_self\">Secukinumab,<\/a> <a class=\"link\" href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Schlagwort.aspx?S=FUTURE-2-Studie,\" target=\"_self\">FUTURE-2-Studie,<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Alle Artikel zum Schlagwort: Secukinumab,<\/strong><\/p>\n<p><a class=\"link1\" style=\"font-weight: bold; color: black;\" href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Artikel.aspx?J=2015&amp;S=67\" target=\"_self\">Dosisabh\u00e4ngige Zunahme schwerwiegender Infektionen bei Rheumapatienten und Therapie mit Biologika<\/a>\u00a0<a class=\"link\" href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Artikel.aspx?J=2015&amp;S=67\" target=\"_self\">2015, <b>49<\/b>, 67<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Verl\u00e4ssliche Daten zu Arzneimitteln<\/strong><\/p>\n<p><strong>DER ARZNEIMITTELBRIEF<\/strong> informiert seit 1967 \u00c4rzte, Medizinstudenten, Apotheker und Angeh\u00f6rige anderer Heilberufe \u00fcber Nutzen und Risiken von Arzneimitteln.<\/p>\n<p><strong>DER ARZNEIMITTELBRIEF<\/strong> erscheint als unabh\u00e4ngige Zeitschrift ohne Werbeanzeigen der Pharmaindustrie. Er wird ausschlie\u00dflich durch seine Leserinnen und Leser, d. h. durch die Abonnenten, finanziert. Wir bitten Sie deshalb um Verst\u00e4ndnis, dass wir aktuelle Artikel nur auszugsweise ver\u00f6ffentlichen k\u00f6nnen.<\/p>\n<p><a href=\"http:\/\/gutepillen-schlechtepillen.de\/pages\/abo-einzelperson.php\" target=\"_blank\"><img decoding=\"async\" title=\"Gute Pillen - Schlechte Pillen ist ein ganz besonderes Projekt.\" src=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" alt=\"GPSP_Banner_AMB_01_2013\" width=\"150\" height=\"150\" \/><\/a> <a href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Abonnement-Einzelnutzer-Studenten.aspx\"><img decoding=\"async\" title=\"Was bringt DER ARZNEIMITTELBRIEF speziell f\u00fcr Studentinnen und Studenten und den Beginn des Berufslebens?\" src=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/2_Studi_Banner_AMB_NEU.jpg\" alt=\"2_Studi_Banner_AMB_NEU\" width=\"150\" height=\"150\" \/><\/a> <a href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/isdb.aspx\"><img decoding=\"async\" title=\"DER ARZNEIMITTELBRIEF als Mitglied im ISDB\" src=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/ISDB_Banner_AMB.jpg\" alt=\"DER ARZNEIMITTELBRIEF als Mitglied im ISDB\" width=\"150\" height=\"150\" \/><\/a> <a href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Abonnieren.aspx\"><img loading=\"lazy\" decoding=\"async\" title=\"Sie k\u00f6nnen den ARZNEIMITTELBRIEF in 4 Preiskategorien abonnieren:\" src=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/07\/1_ABO_Banner_AMB_NEU.jpg\" alt=\"Sie k\u00f6nnen den ARZNEIMITTELBRIEF in 4 Preiskategorien abonnieren:\" width=\"150\" height=\"150\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2015, 49, 85 Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab Fazit: In der FUTURE-2-Studie besserte der Anti-Interleukin-17A-Antik\u00f6rper Secukinumab in den h\u00f6heren hier verwendeten Dosierungen deutlich die Symptome bei Patienten mit aktiver Psoriasisarthritis. Allerdings waren in dieser Studie auch Patienten eingeschlossen worden, die bereits ein Glukokortikosteroid bzw. Methotrexat einnahmen.\u00a0 Bitte abonnieren oder Kennlernartikel anfordern &#8211;&gt; [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[2199,212,2198,2197,2153],"class_list":["post-3530","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-future-2-studie","tag-psoriasis","tag-psoriasisarthritis","tag-schuppenflechte","tag-secukinumab"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab<\/title>\n<meta name=\"description\" content=\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab\" \/>\n<meta property=\"og:description\" content=\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2015-11-25T20:33:35+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"Hiwot\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hiwot\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/\"},\"author\":{\"name\":\"Hiwot\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"headline\":\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab\",\"datePublished\":\"2015-11-25T20:33:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/\"},\"wordCount\":169,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"FUTURE-2-Studie\",\"Psoriasis\",\"Psoriasisarthritis\",\"Schuppenflechte\",\"Secukinumab\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/\",\"name\":\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2015-11-25T20:33:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"description\":\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\",\"name\":\"Hiwot\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"caption\":\"Hiwot\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab","description":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/","og_locale":"de_DE","og_type":"article","og_title":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab","og_description":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2015-11-25T20:33:35+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"Hiwot","twitter_misc":{"Verfasst von":"Hiwot","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/"},"author":{"name":"Hiwot","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"headline":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab","datePublished":"2015-11-25T20:33:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/"},"wordCount":169,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["FUTURE-2-Studie","Psoriasis","Psoriasisarthritis","Schuppenflechte","Secukinumab"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/","name":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2015-11-25T20:33:35+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"description":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c","name":"Hiwot","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","caption":"Hiwot"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts\/3530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/comments?post=3530"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts\/3530\/revisions"}],"predecessor-version":[{"id":3531,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts\/3530\/revisions\/3531"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/media?parent=3530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/categories?post=3530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/tags?post=3530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}